Editor’s summary Chemotherapy for acute myeloid leukemia (AML) can result in cardiotoxicity. Pan et al. found that the angiotensin II receptor type 1 (AGTR1) was increased in
Abstract Phosphoinositide-3-kinase-γ (PI3Kγ) is implicated as a target to repolarize tumour-associated macrophages and promote antitumour immune responses in solid cancers1,2,3,4. However, cancer cell-intrinsic roles of
Abstract Philadelphia chromosome–positive B cell acute lymphoblastic leukemia (B-ALL), characterized by the BCR::ABL1 fusion gene, remains a poor prognosis cancer needing new therapeutic approaches. Transcriptomic profiling identified
Highlights Summary The therapeutic potential for human type 2 innate lymphoid cells (ILC2s) has been underexplored. Although not observed in mouse ILC2s, we found that
Highlights Summary Relapse of acute myeloid leukemia (AML) remains a significant concern due to persistent leukemia-initiating stem cells (LICs) that are typically not targeted by
Summary The first step of oncogenesis is the acquisition of a repertoire of genetic mutations to initiate and sustain the malignancy. An important example of this initiation phase
Highlights Summary Deregulated inflammation is a critical feature driving the progression of tumors harboring mutations in the liver kinase B1 (LKB1), yet the mechanisms linking
Abstract Acute myeloid leukemia (AML) is a hematopoietic malignancy with poor prognosis and limited treatment options. Here we provide a comprehensive census of the bone
Abstract Contemporary chemotherapy for childhood acute lymphoblastic leukemia (ALL) is risk-adapted based on clinical features, leukemia genomics and minimal residual disease (MRD); however, the pharmacological
Abstract Acute myeloid leukemia (AML) is a heterogeneous group of aggressive hematological malignancies commonly associated with treatment resistance, high risk of relapse, and mitochondrial dysregulation.
Abstract The adoptive transfer of T lymphocytes reprogrammed to target tumour cells has demonstrated potential for treatment of various cancers1,2,3,4,5,6,7. However, little is known about
Abstract In cancer, linking epigenetic alterations to drivers of transformation has been difficult, in part because DNA methylation analyses must capture epigenetic variability, which is
Significance mTOR plays a critical role in regulating cell growth and is an important anticancer target. Numerous studies using mTOR inhibitors have shown that mTOR
A basic treatment for leukemia For patients with acute myeloid leukemia, hematopoietic stem cell transplant offers a chance of curing the underlying cancer, in part
Highlights •Bone marrow microenvironment (BMM) facilitates DSB repair activity in leukemia cells •BMM protects leukemia cells from PARP inhibitor (PARPi)-induced synthetic lethality •TGF-β1-TGFβR kinase-SMAD3 pathway
Highlights • AMPK knockout in T cells accelerates acute lymphoblastic leukemia/lymphoma (T-ALL) • Oral treatment with phenformin delays T-ALL development in AMPK-dependent manner • Oral
EDITOR’S CHOICE IN DISEASE & MEDICINE The paper A.L. Boyd et al., “Identification of chemotherapy-induced leukemic-regenerating cells reveals a transient vulnerability of human AML recurrence,”
The tendency of mitochondria to undergo or resist BCL2-controlled apoptosis (so-called mitochondrial priming) is a powerful predictor of response to cytotoxic chemotherapy. Fully exploiting this
An analysis of more than 30 years of research has revealed the underlying cause of the most common form of leukemia in children. Research compiled
SETD2encodes a histone H3 lysine 36 (H3K36) methyltransferase affected by mutations and deletions in a wide variety of cancers. WhetherSETD2loss alone can initiate tumorigenesis has
Multiple myeloma (MM) is a biologically heterogeneous malignancy, however, the mechanisms underlying this complexity are incompletely understood. We report an analysis of the whole-genome sequencing
Researchers report promising results in a Phase 1 trial testing a new cell therapy using chimeric antigen receptor (CAR) T-cell technology on patients suffering from
In 2010, 5-year-old Emily Whitehead was diagnosed with acute lymphoblastic leukemia (ALL). Though her parents were told that if you had to have a kid
Cancer chemotherapeutic agents are developed and approved largely on the back of studies that demonstrate an average efficacy and safety across possibly thousands of patients.
Researchers have halted the progression of leukemia in mice by restoring the enzyme TET2 in hematopoietic stem cells, either by reestablishing its gene expression in
Created by ePubSystems. Contact Us for similar site for your university or institute.